Skip to main content

Arvinas, Inc. (ARVN)

NASDAQ: ARVN · IEX Real-Time Price · USD
73.91 -3.16 (-4.10%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap3.91B
Revenue (ttm)22.59M
Net Income (ttm)-179.55M
Shares Out52.87M
EPS (ttm)-3.30
PE Ration/a
Forward PE17.70
Dividendn/a
Ex-Dividend Daten/a
Volume750,459
Open77.32
Previous Close77.07
Day's Range72.73 - 78.65
52-Week Range28.09 - 108.47
Beta2.00
AnalystsStrong Buy
Price Target130.77 (+76.9%)
Earnings DateNov 4, 2021

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastati...

IndustryPharmaceuticals
IPO DateSep 27, 2018
Employees179
Stock ExchangeNASDAQ
Ticker SymbolARVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for Arvinas stock is "Strong Buy." The 12-month stock price forecast is 130.77, which is an increase of 76.93% from the latest price.

Price Target
$130.77
(76.93% upside)
Analyst Consensus: Strong Buy

News

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Sess...

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose esca...

2 weeks ago - GlobeNewsWire

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

4 weeks ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -132.98% and -96.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today report...

1 month ago - GlobeNewsWire

Neurona Therapeutics Appoints Brad Margus to its Board of Directors

SAN FRANCISCO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today an...

1 month ago - GlobeNewsWire

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented ...

3 months ago - PRNewsWire

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -22.62% and 2.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Recent Price Trend in Arvinas, Inc. (ARVN) is Your Friend, Here's Why

Arvinas, Inc. (ARVN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through ou...

4 months ago - Zacks Investment Research

Analysts Estimate Arvinas, Inc. (ARVN) to Report a Decline in Earnings: What to Look Out for

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

All You Need to Know About Arvinas, Inc. (ARVN) Rating Upgrade to Buy

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

Arvinas, Inc. (ARVN) Moves 13% Higher: Will This Strength Last?

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

4 months ago - Zacks Investment Research

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas.

Other symbols:PFE
4 months ago - Zacks Investment Research

Why Arvinas Jumped 10% Today

The smaller biopharma outfit just inked an encouraging deal with an industry powerhouse.

4 months ago - The Motley Fool

Arvinas, Pfizer Announce $2.4B Licensing Agreement For Protein-Degrader Based Breast Cancer Therapy

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein deg...

Other symbols:PFE
4 months ago - Benzinga

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

– Collaboration combines Arvinas' investigational estrogen receptor-targeting breast cancer therapy with Pfizer's deep experience in breast oncology therapeutics –

4 months ago - GlobeNewsWire

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined...

6 months ago - GlobeNewsWire

Arvinas to Present at the UBS Global Healthcare Virtual Conference

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announc...

6 months ago - GlobeNewsWire

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – – Company to lease approximately 160,000-square-feet to allow continued growth and expansion ...

7 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today rep...

7 months ago - GlobeNewsWire

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

8 months ago - GlobeNewsWire

Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

8 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Arvinas: Q4 Earnings Insights

Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of (...

9 months ago - Benzinga

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research